Pregnancy-Associated Plasma Protein-A
"Pregnancy-Associated Plasma Protein-A" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A product of the PLACENTA, and DECIDUA, secreted into the maternal circulation during PREGNANCY. It has been identified as an IGF binding protein (IGFBP)-4 protease that proteolyzes IGFBP-4 and thus increases IGF bioavailability. It is found also in human FIBROBLASTS, ovarian FOLLICULAR FLUID, and GRANULOSA CELLS. The enzyme is a heterotetramer of about 500-kDa.
|Pregnancy-Associated Plasma Protein-A
- Pregnancy-Associated Plasma Protein-A
- Pregnancy Associated Plasma Protein A
- IGFBP-4 Protease
- IGFBP 4 Protease
- Protease, IGFBP-4
- IGFBP-4-Specific Proteinase
- Insulin-Like Growth Factor-Dependent IGF Binding Protein-4 Protease
- Insulin Like Growth Factor Dependent IGF Binding Protein 4 Protease
- PAPP alpha
- Pregnancy Associated alpha Plasma Protein
- Pregnancy-Associated alpha-Plasma Protein
- IGFBP-4 Metalloproteinase
- IGFBP 4 Metalloproteinase
- Metalloproteinase, IGFBP-4
- Insulin-Like-Growth Factor Binding Protein-4 Protease
- Insulin Like Growth Factor Binding Protein 4 Protease
Below are MeSH descriptors whose meaning is more general than "Pregnancy-Associated Plasma Protein-A".
Below are MeSH descriptors whose meaning is more specific than "Pregnancy-Associated Plasma Protein-A".
This graph shows the total number of publications written about "Pregnancy-Associated Plasma Protein-A" by people in this website by year, and whether "Pregnancy-Associated Plasma Protein-A" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Below are the most recent publications written about "Pregnancy-Associated Plasma Protein-A" by people in Profiles.
First-trimester screening for trisomy 21 by free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A: impact of maternal and pregnancy characteristics. Ultrasound Obstet Gynecol. 2008 May; 31(5):493-502.
First-trimester ultrasound and biochemical markers of aneuploidy and the prediction of preterm or early preterm delivery. Ultrasound Obstet Gynecol. 2008 Feb; 31(2):147-52.
Screening for trisomy 21 by fetal tricuspid regurgitation, nuchal translucency and maternal serum free beta-hCG and PAPP-A at 11 + 0 to 13 + 6 weeks. Ultrasound Obstet Gynecol. 2006 Feb; 27(2):151-5.
Factors affecting women's preference for type of prenatal screening test for chromosomal anomalies. Ultrasound Obstet Gynecol. 2004 Dec; 24(7):735-9.
The effect of temporal variation in biochemical markers of trisomy 21 across the first and second trimesters of pregnancy on the estimation of individual patient-specific risks and detection rates for Down's syndrome. Ann Clin Biochem. 2003 May; 40(Pt 3):219-31.
Temporal changes in maternal serum biochemical markers of trisomy 21 across the first and second trimester of pregnancy. Ann Clin Biochem. 2002 Nov; 39(Pt 6):567-76.
One-stop clinic for assessment of risk for trisomy 21 at 11-14 weeks: a prospective study of 15 030 pregnancies. Ultrasound Obstet Gynecol. 2002 Sep; 20(3):219-25.
Age related detection and false positive rates when screening for Down's syndrome in the first trimester using fetal nuchal translucency and maternal serum free betahCG and PAPP-A. BJOG. 2001 Oct; 108(10):1043-6.
Second trimester levels of pregnancy associated plasma protein-A in cases of trisomy 18. Prenat Diagn. 1999 Dec; 19(12):1127-34.
A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A. Ultrasound Obstet Gynecol. 1999 Apr; 13(4):231-7.